Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages 2111-2117

  Sperduto, Paul W ^a   Kased, Norbert ^b   Roberge, David ^c   Xu, Zhiyuan ^d   Shanley, Ryan ^e   Luo, Xianghua ^e,f   Sneed, Penny K ^b   Chao, Samuel T ^d   Weil, Robert J ^d   Suh, John ^d   Bhatt, Amit ^g   Jensen, Ashley W ^h   Brown, Paul D ^h   Shih, Helen A ⁱ   Kirkpatrick, John ^j   Gaspar, Laurie E ^k   Fiveash, John B ^l   Chiang, Veronica ^m   Knisely, Jonathan P S ^m   Sperduto, Christina Maria ⁿ   Lin, Nancy ^o   Mehta, Minesh ^p   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h MAYO CLINIC   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m YALE CANCER CENTER   (United States)

ⁿ DARTMOUTH COLLEGE   (United States)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Brain metastases; Breast cancer; Estrogen; HER2; Outcomes; Progesterone; Prognosis; Radiation therapy; Stereotactic radiosurgery

Indexed keywords

BRAIN METASTASIS; BREAST CANCER; ESTROGEN; HER2; OUTCOMES; PROGESTERONE; PROGNOSIS; STEREOTACTIC RADIOSURGERY;

DIAGNOSIS; DISEASES; FACTOR ANALYSIS; PATIENT MONITORING; RADIOTHERAPY; REGRESSION ANALYSIS; TUMORS;

BRAIN;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AGE; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GRADED PROGNOSTIC ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; COHORT STUDIES; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84858698969     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.02.027     Document Type: Article

References (55)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. CA Cancer J Clin 2010;60:277-300.
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol 2004;22:2865-2872. (Pubitemid 41079905)
3. Zimm S,Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 1981;48:384-394. (Pubitemid 11127382)
4. Posner JB. Neurologic Complications of Cancer. Philadelphia: FA Davies; 1995.
5. Bendell JC, Domchek SM, Burnstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97: 2972-2977. (Pubitemid 36676250)
6. Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658-5663. (Pubitemid 46631306)
7. Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006;107:696-704. (Pubitemid 44232661)
8. Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast cancer: Importance of prognostic markers of the primary tumor. Cancer 2003;97:545-553. (Pubitemid 36125831)
9. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-944. (Pubitemid 43778983)
10. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30: 1097-1104. (Pubitemid 44299342)
11. Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15:219-225.
12. Kennecke H, Yerushaimi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28: 3271-3277.
13. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 2008;113:2638-2645.
14. Heitz F, Harter P, Lueck HJ, et al. Triple-negative and HER2- overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009;45:2792-2798.
15. th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2009. p. 458-472.
16. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
17. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98: 10869-10874. (Pubitemid 32878711)
18. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER2 is associated with local and distant recurrence after breast conserving therapy. J Clin Oncol 2008;26:2373-2378.
19. Goyal S, Prasad D, Harrell FE, et al. Gamma knife surgery for the treatment of intracranial metastases from breast cancer. J Neurosurg 2005;103:218-223. (Pubitemid 43193895)
20. Dawood S, et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: A single-institution review. Cancer 2010;116:3084-3092.
21. Nam BH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:R20.
22. Lentzsch S, et al. Brain metastases in breast cancer: Prognostic factors and management. Eur J Cancer 1999;35:580-585. (Pubitemid 29192966)
23. Nieder C, et al. Prognostic scores in brain metastases from breast cancer. BMC Cancer 2009;9:105.
24. Kased N, et al. Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys 2009; 75:1132-1140.
25. Muacevic A, et al. Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer 2004;100:1705-1711.
26. Akyurek S, et al. Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am J Clin Oncol 2007;30:310-314. (Pubitemid 46884154)
27. Rades D, et al. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer 2007;110:2587-2592. (Pubitemid 350174946)
28. Ogawa K, et al. Treatment and prognosis of brain metastases from breast cancer. J Neurooncol 2008;86:231-238. (Pubitemid 350263423)
29. Le Scodan R, et al. Brain metastases from breast carcinoma: Validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys 2007;69:839-845. (Pubitemid 47418410)
30. Melisko ME, et al. Brain metastases in breast cancer: Clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 2008;88:359-365.
31. Viani GA, et al. Whole brain radiotherapy for brain metastases from breast cancer: Estimation of survival using two stratification systems. BMC Cancer 2007;7:53.
32. Eichler AF, et al. Survival in patients with brain metastases from breast cancer: The importance of HER-2 status. Cancer 2008;112:2359-2367.
33. Lederman G, Wronski M, Fine M. Fractionated radiosurgery for brain metastases in 43 patients with breast carcinoma. Breast Cancer Res Treat 2001;65:145-154. (Pubitemid 32193618)
34. Firlik KS, et al. Stereotactic radiosurgery for brain metastases from breast cancer. Ann Surg Oncol 2000;7:333-338. (Pubitemid 30397473)
35. Park BB, et al. Prognostic factor analysis in patients with brain metastases from breast cancer: How can we improve the treatment outcomes? Cancer Chemother Pharmacol 2009;63:627-633.
36. Claude L, et al. Lymphopenia: A new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 2005;76:334-339. (Pubitemid 41394285)
37. Mahmoud-Ahmed AS, et al. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study. Int J Radiat Oncol Biol Phys 2002;54:810-817.
38. Gaspar LE, Scott C, Rotman, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-751.
39. Gaspar LE, Scott C, Murray K, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-1006. (Pubitemid 30345599)
40. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008;70:510-514.
41. Komarnicky LT, Phillips TL, Martz K, et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG79-16). Int J Radiat Oncol Biol Phys 1991;20:53-58.
42. Sause WT, Scott C, Kirsch R, et al. Phase I/II trial of accelerated fractionation in brain metastases, RTOG 85-28. Int J Radiat Oncol Biol Phys 1993;26:653-657. (Pubitemid 23220165)
43. Phillips TL, Scott CB, Liebel S, et al. Results of a randomized comparison of radiotherapy and bromodeoxyuridine to radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 1995;33:339-348.
44. Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of RTOG 9104. Int J Radiat Oncol Biol Phys 1997;39:571-574. (Pubitemid 27441421)
45. Sperduto CM, Watanabe Y, Mullan J, et al. A validation study of a new prognostic index for patients with brain metastases: The Graded Prognostic Assessment. J Neurosurg 2008;109: 87-89.
46. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi- institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010;77:655-661.
47. Sperduto PW. What is your patient's GPA and why does it matter? Managing brain metastases and the cost of hope. Int J Radiat Oncol Biol Phys 2010;77:643-644.
48. van Dijk MR, Steyerberg EW, Stenning SP, et al. Survival of patients with nonseminomatous germ cell cancer: A review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer 2004;90:1176-1183. (Pubitemid 38496810)
49. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Wadsworth; 1984.
50. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the rpart routine. Technical Report 61. Rochester, MN: Mayo Clinic, Section of Biostatistics; 1997.
51. Niwinska A, Murawska M, Pogoda K. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 2010;116:4238-4247.
52. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672. (Pubitemid 41464705)
53. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684. (Pubitemid 41464706)
54. thed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2009. p. 408-430.
55. Epstein M, Ma Y, Press MF. ERBB2 Testing: Assessment of status for targeted therapies. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the Breast. 4th ed. Philadelphia, PA: Wolters Kluwer/ Lippincott Williams & Wilkins; 2009. p. 431-442.